Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Kohei ShinmuraSo OkuboSaori KadotaHitomi NakayamaAki SakuraiShuhei KurosawaChisako ItoYoshinobu AisaTomonori NakazatoPublished in: Annals of hematology (2022)